TF and neoplasm: It appears that TF is also a unique pathological angiogenic endothelial cell surface receptor in vivo because of its selective expression on angiogenic VECs in vivo in tumor vasculature [4–7, 9, 14], ocular [18] and endometriotic [21] neovasculature from patients or animal models.